Baltimore Washington Financial Advisors Inc. Sells 6,010 Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

Baltimore Washington Financial Advisors Inc. lessened its holdings in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 13.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 39,023 shares of the specialty pharmaceutical company’s stock after selling 6,010 shares during the period. Baltimore Washington Financial Advisors Inc.’s holdings in Supernus Pharmaceuticals were worth $1,072,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 0.9% during the second quarter. Vanguard Group Inc. now owns 5,345,217 shares of the specialty pharmaceutical company’s stock valued at $176,873,000 after acquiring an additional 49,676 shares during the period. Rice Hall James & Associates LLC lifted its stake in shares of Supernus Pharmaceuticals by 35.1% during the second quarter. Rice Hall James & Associates LLC now owns 1,351,286 shares of the specialty pharmaceutical company’s stock valued at $44,714,000 after acquiring an additional 350,905 shares during the period. Macquarie Group Ltd. lifted its stake in shares of Supernus Pharmaceuticals by 8.5% during the second quarter. Macquarie Group Ltd. now owns 1,079,001 shares of the specialty pharmaceutical company’s stock valued at $35,705,000 after acquiring an additional 84,846 shares during the period. Neumeier Poma Investment Counsel LLC lifted its stake in shares of Supernus Pharmaceuticals by 1.1% during the second quarter. Neumeier Poma Investment Counsel LLC now owns 957,401 shares of the specialty pharmaceutical company’s stock valued at $31,680,000 after acquiring an additional 10,170 shares during the period. Finally, Provident Investment Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 13.8% during the second quarter. Provident Investment Management Inc. now owns 726,333 shares of the specialty pharmaceutical company’s stock valued at $24,034,000 after acquiring an additional 88,099 shares during the period. Institutional investors own 99.12% of the company’s stock.

In related news, CEO Jack A. Khattar bought 7,200 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average price of $26.39 per share, with a total value of $190,008.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.57% of the company’s stock.

NASDAQ:SUPN traded up $0.40 during mid-day trading on Thursday, hitting $26.58. The company had a trading volume of 5,364 shares, compared to its average volume of 568,400. Supernus Pharmaceuticals Inc has a fifty-two week low of $24.77 and a fifty-two week high of $49.47. The business’s fifty day moving average is $27.29 and its two-hundred day moving average is $31.51. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.53 and a current ratio of 2.72. The firm has a market cap of $1.39 billion, a P/E ratio of 13.06, a P/E/G ratio of 0.88 and a beta of 1.61.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.05. Supernus Pharmaceuticals had a return on equity of 22.36% and a net margin of 25.66%. The firm had revenue of $104.70 million for the quarter, compared to analyst estimates of $109.67 million. During the same quarter in the prior year, the firm posted $0.57 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. Equities analysts forecast that Supernus Pharmaceuticals Inc will post 2.16 earnings per share for the current year.

Several equities analysts have recently issued reports on the company. Jefferies Financial Group set a $46.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 30th. Cowen set a $50.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 7th. BidaskClub lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 9th. Zacks Investment Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 9th. Finally, TheStreet lowered Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Thursday, August 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $53.38.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Recommended Story: What is the Coverage Ratio?

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.